A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL.

Trial Profile

A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 20 Mar 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 19 Mar 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top